Matinas BioPharma Holdings Inc (MTNB) PT Set at $6.00 by Maxim Group
Matinas BioPharma Holdings Inc (NASDAQ:MTNB) has been assigned a $6.00 price objective by equities research analysts at Maxim Group in a report issued on Tuesday. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 319.58% from the company’s current price.
Separately, Roth Capital initiated coverage on shares of Matinas BioPharma Holdings in a research report on Monday, July 10th. They issued a “buy” rating and a $9.00 target price for the company.
Matinas BioPharma Holdings (MTNB) traded up 14.40% during trading on Tuesday, hitting $1.43. 640,549 shares of the stock were exchanged. The stock’s market capitalization is $130.70 million. Matinas BioPharma Holdings has a 52 week low of $0.63 and a 52 week high of $3.99. The firm has a 50-day moving average of $1.66 and a 200-day moving average of $2.56.
Matinas BioPharma Holdings (NASDAQ:MTNB) last announced its earnings results on Tuesday, May 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.21. The business had revenue of $0.02 million during the quarter. Matinas BioPharma Holdings had a negative net margin of 30,034.20% and a negative return on equity of 1,227.85%. Equities research analysts anticipate that Matinas BioPharma Holdings will post ($0.26) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the company. Spark Investment Management LLC purchased a new stake in Matinas BioPharma Holdings during the first quarter valued at $105,000. Alps Advisors Inc. purchased a new stake in Matinas BioPharma Holdings during the second quarter valued at $139,000. Schwab Charles Investment Management Inc. purchased a new stake in Matinas BioPharma Holdings during the second quarter valued at $152,000. Segantii Capital Management Ltd purchased a new stake in Matinas BioPharma Holdings during the first quarter valued at $166,000. Finally, KCG Holdings Inc. purchased a new stake in Matinas BioPharma Holdings during the first quarter valued at $193,000.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.